| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return |
|---|---|---|---|---|---|
|
CH:LONN
Lonza Group Ltd
|
Jul 14, 2026 | BUY |
Strong Buy
+10.2% avg upside
20 analysts
|
$720.00
22.42% Upside
|
· |
|
IT:1SXP
SCHOTT Pharma AG & Co. KGaA
|
Jul 09, 2026 | BUY |
Buy
+4.3% avg upside
6 analysts
|
$21.00
2.39% Upside
|
· |
|
CH:PPGN
PolyPeptide Group AG
|
Jul 07, 2026 | HOLD |
Buy
-23.5% avg upside
3 analysts
|
$44.00
3.69% Downside
|
· |
|
GB:SN
Smith & Nephew
|
Jun 29, 2026 | HOLD |
Strong Buy
+1228.1% avg upside
16 analysts
|
$1350.00
16.84% Upside
|
· |
|
GB:OXB
Oxford BioMedica
|
Jun 24, 2026 | BUY |
Strong Buy
+50.9% avg upside
4 analysts
|
$1140.00
74.27% Upside
|
· |
|
GB:4BB
4basebio UK Societas
|
Jun 15, 2026 | BUY |
Strong Buy
+166.7% avg upside
1 analyst
|
$1400.00
166.68% Upside
|
· |
|
CH:BANB
Bachem Holding AG
|
Jun 09, 2026 | BUY |
Hold
-1.5% avg upside
4 analysts
|
$110.00
47.84% Upside
|
· |
|
GB:ONT
Oxford Nanopore Technologies PLC
|
May 26, 2026 | BUY |
Strong Buy
+80.8% avg upside
6 analysts
|
$225.00
94.02% Upside
|
· |
|
DE:AFX
Carl Zeiss Meditec
|
May 12, 2026 | HOLD |
Hold
+57.2% avg upside
13 analysts
|
$32.00
1.44% Upside
|
· |
|
FR:DIM
Sartorius Stedim Biotech
|
May 06, 2026 | BUY |
Strong Buy
+32.7% avg upside
11 analysts
|
$210.00
10.93% Upside
|
· |
|
DE:SRT3
Sartorius
|
May 06, 2026 | HOLD |
Buy
+10.6% avg upside
18 analysts
|
$220.00
11.83% Downside
|
· |
|
DE:EVT
Evotec
|
May 04, 2026 | BUY |
Buy
+334.0% avg upside
8 analysts
|
$10.00
102.25% Upside
|
· |
|
CH:SFZN
Siegfried Holding AG
|
Mar 16, 2026 | HOLD |
Hold
+26.1% avg upside
3 analysts
|
$96.00
31.67% Upside
|
· |
|
GB:CVSG
CVS Group plc
|
Mar 04, 2026 | BUY |
Buy
+19.9% avg upside
4 analysts
|
$1900.00
52.21% Upside
|
· |
|
GB:UPR
Uniphar PLC
|
Feb 24, 2026 | BUY |
Strong Buy
+1.9% avg upside
3 analysts
|
$408.84
2.24% Upside
|
· |
|
LZAGY
Lonza Group
|
Feb 11, 2026 | BUY |
Strong Buy
+19.3% avg upside
2 analysts
|
— | +11.1% |
|
SSB
SouthState Corporation
|
Jan 07, 2025 | BUY |
Strong Buy
+28.9% avg upside
16 analysts
|
$284.92
183.66% Upside
|
+5.3% |
|
GB:SPI
Spire Healthcare
|
Nov 19, 2024 | BUY |
Strong Buy
+35.3% avg upside
6 analysts
|
$310.00
42.83% Upside
|
· |
|
GB:CTEC
ConvaTec
|
Mar 23, 2023 | HOLD |
Strong Buy
+38.0% avg upside
17 analysts
|
$215.00
0.07% Upside
|
· |
|
CH:MOLN
Molecular Partners AG
|
Jul 12, 2021 | BUY |
Strong Buy
+551.0% avg upside
5 analysts
|
$26.00
717.66% Upside
|
· |
|
SE:HNSA
Hansa Biopharma AB
|
Apr 13, 2021 | BUY |
Strong Buy
+320.5% avg upside
4 analysts
|
$287.00
752.16% Upside
|
· |
|
GB:IPO
IP Group plc
|
Nov 02, 2018 | BUY |
Strong Buy
+7413.7% avg upside
3 analysts
|
$160.00
150.37% Upside
|
· |
|
MDXH
MDxHealth
|
Apr 24, 2018 | BUY |
Strong Buy
+1421.5% avg upside
8 analysts
|
$6.95
1516.29% Upside
|
· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.